# Almond LDL Cholesterol Meta-analysis: What the Evidence Says
Canonical: https://www.migaku.app/guides/almond-ldl-cholesterol-meta-analysis-evidence-review
Category: evidence-review
Summary: Almond LDL Cholesterol Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are sy
Last reviewed: 2026-07-25
Reviewed by: Migaku Evidence Review
# Almond LDL Cholesterol Meta-analysis: What the Evidence Says

## Quick Answer

Almond LDL Cholesterol Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 systematic review, 1 narrative review.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Blood Lipid Levels in Response to Almond Consumption: A Systematic Review and Meta-Analysis of Randomized Controlled Trials | systematic review | 1 | 2025-08-28 | 10.3390/nu17172791 |
| The Impact of Sugar Source on the Relationships Between Free Sugars Intake and Health: A Secondary Analysis | narrative review | 3 | 2026-04-22 | 10.3390/nu18091323 |

## What The Sources Report

- While certain CVD risk factors are not modifiable (i.e., family history, older age, male gender, and certain ethnicities [African Americans, Hispanics, Latinos, and Southeast Asians]), other risk factors, including hypertension, diabetes, obesity, smoking, poor diet, sedentary lifestyle, and hyperlipidemia, are modifiable. [Musa-Veloso Kathy (2025); evidence level 1]
- Hyperlipidemia is a major CVD risk factor, with elevations in atherogenic lipids contributing to atherosclerosis, an inflammatory disease characterized by fatty deposits in vessel walls, leading to their narrowing and hardening. [Musa-Veloso Kathy (2025); evidence level 1]
- Conversely, a meta-analysis described in a report by the European Food Safety Authority (EFSA) on the tolerable upper intake level for dietary sugars identified a causal relationship with FS and risk of obesity and dyslipidemia from RCTs. [Peregoy Jennifer A. (2026); evidence level 3]
- However, data from prospective cohorts did not suggest a positive relationship between intake of FS and risk of obesity or dyslipidemia. [Peregoy Jennifer A. (2026); evidence level 3]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For almond LDL cholesterol meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Musa-Veloso Kathy (2025). Blood Lipid Levels in Response to Almond Consumption: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. DOI: 10.3390/nu17172791. PMCID: PMC12430622. PMID: 40944180. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12430622/
- Peregoy Jennifer A. (2026). The Impact of Sugar Source on the Relationships Between Free Sugars Intake and Health: A Secondary Analysis. DOI: 10.3390/nu18091323. PMCID: PMC13164700. PMID: 42123925. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13164700/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.